2023-08-10 16:04:28 ET
Indian drugmaker Dr. Reddy's Laboratories ( NYSE: RDY ) said it has launched a generic equivalent of AstraZeneca's ( AZN ) diabetes medication Kombiglyze XR for the US market.
The product, which is an extended release formulation of saxagliptin and metformin hydrochloride, is used to treat Type 2 diabetes. The drug will be available in strengths of 2.5mg/1000mg, 5mg/500mg and 5mg/1000mg.
Kombliglyze XR was co-developed with Bristol-Myers Squibb ( BMY ). The product was approved by the FDA in 2010 , according to AstraZeneca.
More on Dr. Reddy's:
Dr. Reddy's Laboratories Limited 2024 Q1 - Results - Earnings Call Presentation
Dr Reddy's Laboratories Ltd ( RDY ) Q1 2024 Earnings Call Transcript
Dr. Reddy's GAAP EPS of ?84.22, revenue of ?6.7B
For further details see:
Dr. Reddy's launches generic version of Kombiglyze XR in US